Caxton Associates (UK)’s RxSight RXST Stock Holding History

Caxton Associates (UK)’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-70,279	Closed	-$914K	–	905
2025 Q2	$914K	Buy	+70,279	New	+$1.06M	0.02%	332

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (UK)'s RXST Position: Q3 2025 in Review

Caxton Associates (UK) sold out of RxSight (RXST) in Q3 2025, closing a stake of 70,279 shares — an estimated $914K sold.

Caxton Associates (UK) first reported a position in RXST in Q2 2025 and held it in 1 quarter. The position peaked at $914K in Q2 2025. 160 funds tracked by Wall St. Rank hold RXST as of Q3 2025.

Caxton Associates (UK) reported no remaining RxSight position as of Q3 2025 after selling out during the quarter.
Caxton Associates (UK) sold 70,279 RxSight shares in Q3 2025, an estimated $914K.
Caxton Associates (UK) first reported a position in RxSight in Q2 2025 and held it in 1 quarter.
Caxton Associates (UK)'s RxSight position peaked at $914K in Q2 2025.
160 funds tracked by Wall St. Rank held RxSight as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.